The lawsuit centers on claims that ADMA Biologics misled the market throughout the specified period. According to the complaint, the company allegedly failed to disclose an internal related-party transaction and utilized channel stuffing to artificially inflate reported revenue figures. Furthermore, the filing asserts that the company lacked the necessary internal controls to maintain accurate financial reporting.
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics, Inc. securities between August 9, 2024, and March 25, 2026, face an August 10, 2026, deadline to serve as lead plaintiff in a pending class action lawsuit filed by The Rosen Law Firm regarding allegations of securities fraud.
Shareholders who believe they suffered financial losses due to these practices can participate in the litigation to seek potential compensation. Participation does not require the payment of out-of-pocket legal fees, as the case is being managed under a contingency fee arrangement. Investors interested in serving as a representative party must file a motion with the Court by the August 10 deadline, though individual investors may choose to remain absent class members and await the outcome of the proceedings.
Comments (0)
No comments yet. Be the first!